Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nemiralisib
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Nemiralisib is a highly selective, inhaled small molecule inhibitor of phosphoinositide 3‑kinase delta (PI3Kδ), developed primarily for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and immunodeficiency disorders. It acts as an immunomodulatory agent with anti-inflammatory properties by inhibiting PI3Kδ activity in immune cells. Nemiralisib was developed by GlaxoSmithKline and has been investigated in multiple clinical trials for acute exacerbations of COPD and other respiratory conditions. Despite demonstrating an acceptable safety profile when administered via inhalation, development for all major indications has been discontinued[5][6][7][8].
- Other names
- nemiralisib [usan]OEP8JJ3OZROEP-8JJ3OZROEP 8JJ3OZR
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on nemiralisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nemiralisib.